Fact sheet: CS Inv5CS(L) GblBiotechInnEq

Fund information
Fund name
CS Investment 5 CS (Lux) Global Biotech Innovators Equity B USD
Fund manager company
Credit Suisse Fund Management
Fund type
Offshore Fund
Fund manager
  • Dr.. Irene Beatrice Püttnersince 01/02/2008
Fund objective
This sector-based equity fund globally invests in stocks of biotechnology companies to achieve long-term capital appreciation while maintaining an adequate distribution of risks. It offers access to one of the fastest-growing segments of the health sector, and opportunity to participate in growth in value tied to clinical progress of innovative products from early stage to those ready to be brought to market. The fund invests in numerous therapeutics areas, as well as diagnosis and preventative treatments. The portfolio is not constrained either in terms of geography or by market capitalization. The NASDAQ Biotechnology TR serves as the benchmark.
Benchmark
  • NASDAQ Biotechnology
Investment style
Growth
Investment method
Shares
Quick stats
1 Year return
0.9%
1 Year rank in sector
26/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
2.2%
Fund size
£178m (£241m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
178
Top in this sector
Fund name1 Year
Variopartner SICAV MVGbMdtcF26.2%
BB Medtech25.2%
Fidelity Gbl Health Care22.4%
Pictet Health19.7%
Charlemagne MagnaBiphrm18.5%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA87.7%
    Denmark4.6%
    Switzerland4%
    Others2.8%
    Money Market1%
  • Biotechnology/Medical92.5%
    Pharmaceuticals6.6%
    Cash & Cash Equivalents0.9%
  • US Equities87.7%
    Danish Equities4.6%
    Swiss Equities4%
    International Equities2.8%
    Cash & Cash Equivalents1%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund5.4%16.6%17.6%0.9%34%203.2%
Sector2.6%7.9%12.5%5.3%41.5%134.2%
Rank within sector4 / 325 / 328 / 3126 / 3116 / 242 / 24
Quartile1st1st2nd4th3rd1st
Calendar performance
 YTD - 20162015201420132012
Fund-11.4%9.4%31.1%61.1%35.1%
Sector-3.5%7.2%28.1%41%16.7%
Rank within sector27 / 3112 / 2918 / 265 / 241 / 24
Quartile4th2nd3rd1st1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
-6.12
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.51
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.29
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
25.9
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
12.81
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
-0.12
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.87
Price movement
52 week high466.11
52 week low319.66
Current bid price-
Current offer price-
Current mid price403.13
Region
1USA87.67%
2Denmark4.57%
3Switzerland3.96%
4Others2.8%
5Money Market1%
Industry sector
1Biotechnology/Medical92.53%
2Pharmaceuticals6.57%
3Cash & Cash Equivalents0.89%
Asset type
1US Equities87.67%
2Danish Equities4.57%
3Swiss Equities3.96%
4International Equities2.8%
5Cash & Cash Equivalents1%
Individual holdings
1CELGENE CORP7.34%
2BIOGEN INC7.12%
3AMGEN INC6.43%
4GILEAD SCIENCES INC5.57%
5REGENERON PHARMACEUTICALS INC5.46%
6BIOMARIN PHARMACEUTICAL4.46%
7INCYTE CORP4.03%
8ALEXION PHARMACEUTICALS INC3.79%
9VERTEX PHARMACEUTICAL3.79%
Management
Fund manager group
Credit Suisse
Fund manager company
Credit Suisse Fund Management
Fund type
Offshore Fund
Fund objective
This sector-based equity fund globally invests in stocks of biotechnology companies to achieve long-term capital appreciation while maintaining an adequate distribution of risks. It offers access to one of the fastest-growing segments of the health sector, and opportunity to participate in growth in value tied to clinical progress of innovative products from early stage to those ready to be brought to market. The fund invests in numerous therapeutics areas, as well as diagnosis and preventative treatments. The portfolio is not constrained either in terms of geography or by market capitalization. The NASDAQ Biotechnology TR serves as the benchmark.
Benchmark
  • NASDAQ Biotechnology
Investment style
Growth
Investment method
Shares
Fund manager
NameSinceBiography
Dr.. Irene Beatrice Püttner01/02/2008Dr Irene Püttner, a former expert in molecular biology/biochemistry. Dr Püttner has previous investment experience within the Life Sciences area, and 14 years experience in research and business development within the Biotech and Pharmaceutical industry in both Europe and the United States. The Investment Management team will have access to Sarasin's dedicated Healthcare Research team who have specific healthcare industry expertise.
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, Transparent for German Tax, Reporting Fund Status, UCITS IV Compliant
Domicile
No data available.
Fund for sale in
Austria, Switzerland, Chile, Germany, Spain, France, United Kingdom, Italy, Liechtenstein, Luxembourg, Offshore, Singapore
CS Investment 5 CS (Lux) Global Biotech Innovators Equity B USD
Initial charge5%
Annual charge1.92%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.2%
Total expense ratio (TER)2.23%
Bid price-
Offer price-
Mid price403.13
CurrencyUSD
Price updated28/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeC331
CS Investment 5 CS (Lux) Global Biotech Innovators Equity BH EUR
Initial charge5%
Annual charge1.92%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.2%
Total expense ratio (TER)2.23%
Bid price-
Offer price-
Mid price268.44
CurrencyEUR
Price updated28/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeCTR3
CS Investment 5 CS (Lux) Global Biotech Innovators Equity BH USD
Initial charge5%
Annual charge1.92%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.2%
Total expense ratio (TER)2.23%
Bid price-
Offer price-
Mid price163.28
CurrencyUSD
Price updated05/07/2012
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFML2
CS Investment 5 CS (Lux) Global Biotech Innovators Equity EB USD
Initial charge3%
Annual charge0.9%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.22%
Total expense ratio (TER)1.19%
Bid price-
Offer price-
Mid price1168.25
CurrencyUSD
Price updated28/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFI9U
CS Investment 5 CS (Lux) Global Biotech Innovators Equity IB USD
Initial charge3%
Annual charge0.9%
Min single investment£500,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.18%
Total expense ratio (TER)1.21%
Bid price-
Offer price-
Mid price441.67
CurrencyUSD
Price updated28/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeC332
CS Investment 5 CS (Lux) Global Biotech Innovators Equity IBH EUR
Initial charge3%
Annual charge0.9%
Min single investment£500,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.24%
Bid price-
Offer price-
Mid price1098.43
CurrencyEUR
Price updated28/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeFNEJ
CS Investment 5 CS (Lux) Global Biotech Innovators Equity UB USD
Initial charge5%
Annual charge1.15%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.53%
Bid price-
Offer price-
Mid price87.7
CurrencyUSD
Price updated28/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFSES
CS Investment 5 CS (Lux) Global Biotech Innovators Equity UBH EUR
Initial charge5%
Annual charge1.15%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.47%
Bid price-
Offer price-
Mid price86.93
CurrencyEUR
Price updated28/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFSET
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.